Gene therapy platform for Stargardt macular degeneration receives IND clearance
The FDA has granted investigational new drug clearance to Nanoscope Therapeutics for a phase 2 trial investigating MCO-010 in patients with Stargardt macular degeneration, according to a press release.
“This is another important milestone for Nanoscope, giving us the opportunity of conducting a second clinical trial in the U.S. of our proprietary MCO gene therapy platform, designed to restore vision for patients suffering from retinal degenerative diseases,” Sulagna Bhattacharya, CEO of Nanoscope Therapeutics, said in the release.
MCO-010, a “multi-characteristic opsin ambient-light activatable optogenetic monotherapy,” is being evaluated in a phase 2b multicenter, randomized, sham-controlled, double-masked study in patients with retinitis pigmentosa, according to the release.
Nanoscope is planning to begin the phase 2 clinical trial in Stargardt macular degeneration in the first half of 2022.